AlzeCure Pharma Receives First Tranche of EU Grant for Alzheimer's Drug Trial

MT Newswires · 4d ago
08:09 AM EST, 12/03/2025 (MT Newswires) -- AlzeCure Pharma (ALZCUR.ST) said Wednesday that it received the first payment from a 2.5 million-euro funding from the European Innovation Council for the phase 2a trial of NeuroRestore ACD856, its Alzheimer's disease drug candidate. The Swedish pharmaceutical company added that previous clinical studies showed that ACD856, which works by improving brain signaling, was safe and activates neuronal pathways.